July 25, 2018 06:36 AM EDTUpdated 08:28 AM
Bioregnum
R&D
Opinion

This is it? GSK rolls out a buzzy new R&D plan long on as­pi­ra­tions and short on per­for­mance goals

Glax­o­SmithK­line set out to kick­start some en­thu­si­asm for its pipeline this morn­ing. But CEO Em­ma Walm­s­ley and her new R&D chief Hal Bar­ron clear­ly have …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Watch Post-Hoc Live: Trump's 'most fa­vored na­tion' plan to cut drug prices

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

It's been three months with­out a biotech IPO

A service from the Financial Times